Angiotensin and captopril increase alcohol intake

Detection of interactions between genetic marker sets and environment in a genome-wide study of hypertension

As human complex diseases are influenced by the interplay of genes and environment, detecting gene-environment interactions ( G × E ) can shed light on biological mechanisms of diseases and play an important role in disease risk prediction. Development of powerful quantitative tools to incorporate G × E in complex diseases has potential to facilitate the accurate curation and analysis of large genetic epidemiological studies. However, most of existing methods that interrogate G × E focus on the interaction effects of an environmental factor and genetic variants, exclusively for common or rare variants. In this study, we proposed two tests, MAGEIT_RAN and MAGEIT_FIX, to detect interaction effects of an environmental factor and a set of genetic markers containing both rare and common variants, based on the MinQue for Summary statistics. The genetic main effects in MAGEIT_RAN and MAGEIT_FIX are modeled as random or fixed, respectively. Through simulation studies, we illustrated that both tests had type I error under control and MAGEIT_RAN was overall the most powerful test. We applied MAGEIT to a genome-wide analysis of gene-alcohol interactions on hypertension in the Multi-Ethnic Study of Atherosclerosis. We detected two genes, CCNDBP1 and EPB42, that interact with alcohol usage to influence blood pressure. Pathway analysis identified sixteen significant pathways related to signal transduction and development that were associated with hypertension, and several of them were reported to have an interactive effect with alcohol intake. Our results demonstrated that MAGEIT can detect biologically relevant genes that interact with environmental factors to influence complex traits.

The effect of telmisartan, an angiotensin receptor blocker, on alcohol consumption and alcohol-induced dopamine release in the nucleus accumbens

Alcohol use disorder remains a major health problem. The mesocorticolimbic dopaminergic system, including the nucleus accumbens region and multiple neural circuits, is involved in its complex underlying mechanism. For instance, alcohol intake stimulates the central and peripheral renin-angiotensin system and increases angiotensin II levels, which predominantly affect angiotensin 1 receptors both in the periphery and in the brain. In this study, we aimed to investigate the effects of the intracerebroventricularly-administered angiotensin 1 receptor blocker telmisartan on the alcohol consumption of male Sardinian alcohol-preferring (sP) rats and on the alcohol-induced dopamine levels in the nucleus accumbens region in Wistar rats. Acute intracerebroventricular administration of telmisartan (100 nM) reduced the alcohol intake for 24 hours without affecting food and water consumption in sP rats. Acute intracerebroventricular injection of the opioid receptor antagonist naloxone (75 nM), tested as a reference compound, also reduced the alcohol consumption in sP rats; however, naloxone's effect lasted only for 30 minutes. In microdialysis experiments, telmisartan administered intracerebroventricularly did not change dopamine levels in the nucleus accumbens that had been induced by acute intraperitoneal alcohol administration in Wistar rats. According to these results, further studies are needed to elucidate the role of the renin-angiotensin system on alcohol use disorder pathophysiology.

Captopril and losartan attenuate behavioural sensitization in mice chronically exposed to toluene

Inhalants are consumed worldwide for recreational purposes. The main component found in many inhalants is toluene. One of the most deleterious behavioural effects caused by chronic exposure to inhalants is addiction. This response has been associated with activation of the mesolimbic dopaminergic pathway, and it is known that the renin angiotensin system plays a role in the modulation of this dopaminergic system. In the present work, we hypothesize that blockade of the RAS with angiotensin converting enzyme inhibitors or angiotensin II type 1 receptor blockers is able to attenuate the addictive response induced by toluene. We exposed mice to toluene for four weeks to induce locomotor sensitization. In the second phase of the work, captopril or losartan were administered for 20 days. Subsequently, the expression of behavioural sensitization was evaluated with a toluene challenge. To exclude false associations between the observed responses and treatments, motor coordination and blood pressure were analysed in animals treated with captopril or losartan. At the end of the behavioural studies, animal brains were harvested and Ang II/Ang-(1-7) and Ang-(1-7)/Ang II ratios were analysed in the nucleus accumbens (NAc) and prefrontal cortex (PFCx). The results showed that toluene induced behavioural sensitization, while captopril or losartan treatment attenuated the expression of this response. No significant differences were observed in motor coordination or blood pressure. Repeated toluene administration decreased Ang-(1-7)/Ang II ratio in the PFCx. On the other hand, treatment with captopril or losartan decreased the Ang II/Ang-(1-7) ratio and enhanced the Ang-(1-7)/Ang II ratio in the NAc. This work suggests that blockade of RAS attenuates the toluene-induced behavioural sensitization.

Effects of microinjection of angiotensin II and captopril to VTA on morphine self-administration in rats

The dopaminergic mesolimbic system is considered to be crucial in rewarding actions of opiates. Recent studies have suggested probable interaction between the renin-angiotensin and mesolimbic dopaminergic systems. The present study was undertaken to investigate the effects of Ang II and captopril injection into VTA on morphine self-administration. Male Wistar rats were initially trained to receive small pellets of food by pressing the active lever in self-administration apparatus. The animals were divided into 4 groups (saline, morphine, captopril and Ang II) and were placed in self-administration apparatus and allowed to self-administer morphine (0.5 mg per infusion all test groups) or saline (saline group) during consecutive days, for 2 h/sessions. Captopril (30 mug) and Ang II (0.25 nmol) were injected into the VTA in the corresponding groups before each session. The numbers of active and passive levers pressed in each group have been recorded. The number of active lever pressing of morphine group was significantly higher than saline group (p < 0.001). In Ang II group, the number of active lever pressing was significantly lower than morphine group (p < 0.01). This study suggests the probable interaction between Ang II and opioid system in the VTA.

Targeting brain angiotensin and corticotrophin-releasing hormone systems interaction for the treatment of mood and alcohol use disorders

The brain renin-angiotensin system (RAS) participates importantly in the regulation of endocrine, autonomic, and behavioral response to stress. Recent data indicate that central action of AT(1) receptor antagonists can reduce anxiety symptoms in experimental animals. Furthermore, central inhibition of RAS activity decreases ethanol intake in an animal model of alcoholism. Pathological anxiety responses and the development of substance dependence are both critically mediated through corticotrophin-releasing hormone (CRH) systems, and the RAS is positioned to interact both with hypothalamic as well as extrahypothalamic CRH systems. The thesis of this paper is that the RAS is part of the neurochemical dysregulation underlying negative affective states, anxiety disorders, and ethanol dependence and that medications targeting the RAS should be considered to augment the treatment of these disorders.

Impaired spatial memory and altered dendritic spine morphology in angiotensin II type 2 receptor-deficient mice

Mental retardation is the most frequent cause of serious handicap in children and young adults. Mutations in the human angiotensin II type 2 receptor (AT2) have been implicated in X-linked forms of mental retardation. We here demonstrate that mice lacking the AT2 receptor gene are significantly impaired in their performance in a spatial memory task and in a one-way active avoidance task. As no difference was observed between the genotypes in fear conditioning, the detected deficit in spatial memory may not relate to fear. Notably, receptor knockout mice showed increased motility in an activity meter and elevated plus maze. Importantly, these mice are characterized by abnormal dendritic spine morphology and length, both features also found to be associated with some cases of mental retardation. These findings suggest a crucial role of AT2 in normal brain function and that dysfunction of the receptor has impact on brain development and ultrastructural morphology with distinct consequences on learning and memory.

Plasticity and impact of the central renin–angiotensin system during development of ethanol dependence

Pharmacological and genetic interference with the renin-angiotensin system (RAS) seems to alter voluntary ethanol consumption. However, understanding the influence of the RAS on ethanol dependence and its treatment requires modeling the neuroadaptations that occur with prolonged exposure to ethanol. Increased ethanol consumption was induced in rats through repeated cycles of intoxication and withdrawal. Expression of angiotensinogen, angiotensin-converting enzyme, and the angiotensin II receptor, AT1a, was examined by quantitative reverse transcription polymerase chain reaction. Increased ethanol consumption after a history of dependence was associated with increased angiotensinogen expression in medial prefrontal cortex but not in nucleus accumbens or amygdala. Increased angiotensinogen expression also demonstrates that the astroglia is an integral part of the plasticity underlying the development of dependence. The effects of low central RAS activity on increased ethanol consumption were investigated using either spirapril, a blood-brain barrier-penetrating inhibitor of angiotensin-converting enzyme, or transgenic rats (TGR(ASrAOGEN)680) with reduced central angiotensinogen expression. Spirapril reduced ethanol intake in dependent rats compared to controls. After induction of dependence, TGR(ASrAOGEN)680 rats had increased ethanol consumption but to a lesser degree than Wistar rats with the same history of dependence. These data suggest that the central RAS is sensitized in its modulatory control of ethanol consumption in the dependent state, but pharmacological or genetic blockade of the system appears to be insufficient to halt the progression of dependence.

Central Overexpression of Angiotensin AT1AReceptors Prevents Dopamine D2Receptor Regulation of Alcohol Consumption in Mice

BACKGROUND

While angiotensin receptors are found on the soma and terminals of dopaminergic neurons, controversy surrounds the potential role of angiotensin in alcohol consumption.

METHODS

Using a transgenic mouse with a brain-specific overexpression of angiotensin AT(1A) receptors (NSE-AT(1A) mice), we have examined the role of angiotensin in alcohol consumption and alcohol-induced regulation of the dopaminergic system.

RESULTS

The functional relevance of the overexpressed AT(1A) receptors was confirmed by an exaggerated rehydration response following 24-hour dehydration. NSE-AT(1A) mice showed a high preference for alcohol (similar to wild-type mice); yet, raclopride treatment had no effect on alcohol consumption in NSE-AT(1A) mice, while significantly reducing consumption in wild-type mice. In contrast, NSE-AT(1A) mice showed enhanced sensitivity to raclopride compared with wild types in terms of D(2) receptor up-regulation within the ventral mesencephalon. In addition, striatal D(2) receptors in NSE-AT(1A) mice were sensitive to up-regulation by chronic alcohol consumption.

CONCLUSIONS

Collectively, these data imply that while expression of angiotensin AT(1A) receptors on striatal neurons has no impact upon basal alcohol consumption or preference, AT(1A) receptors do modulate the sensitivity of dopamine D(2) receptors to regulation by alcohol and the ability of a D(2) receptor antagonist to reduce consumption.

Alcohol-related genes: contributions from studies with genetically engineered mice

Since 1996, nearly 100 genes have been studied for their effects related to ethanol in mice using genetic modifications including gene deletion, gene overexpression, gene knock-in, and occasionally by studying existing mutants. Nearly all such studies have concentrated on genes expressed in brain, and the targeted genes range widely in their function, including most of the principal neurotransmitter systems, several neurohormones, and a number of signaling molecules. We review 141 published reports of effects (or lack thereof) of 93 genes on responses to ethanol. While most studies have focused on ethanol self-administration and reward, and/or sedative effects, other responses studied include locomotor stimulation, anxiolytic effects, and neuroadaptation (tolerance, sensitization, withdrawal). About 1/4 of the engineered mutations increase self-administration, 1/3 decrease it, and about 40% have no significant effect. In many cases, the effects on self-administration are rather modest and/or depend on the specific experimental procedures. In some cases, genes in the background strains on which the mutant is placed are important for results. Not surprisingly, review of the systems affected further supports roles for serotonin, gamma-aminobutyric acid, opioids and dopamine, all of which have long been foci of alcohol research. Novel modulatory effects of protein kinase C and G protein-activated inwardly rectifying K+ (GIRK) channels are also suggested. Some newer research with cannabinoid systems is promising, and has led to ongoing clinical trials.

Central angiotensin II controls alcohol consumption via its AT1 receptor

Pharmacological and genetic manipulations of the renin-angiotensin system (RAS) have been found to alter the voluntary consumption of alcohol. Here we characterize the role of central angiotensin II (Ang II) in alcohol intake first by using transgenic rats that express an antisense RNA against angiotensinogen and consequently have reduced Ang II levels exclusively in the central nervous system [TGR(ASrAOGEN)680]. These rats consumed markedly less alcohol in comparison to their wild-type controls. Second, Spirapril, an inhibitor of the angiotensin-converting enzyme (ACE), which passes the blood-brain barrier, did not influence the alcohol consumption in the TGR(ASrAOGEN)680, but it significantly reduced alcohol intake in wild-type rats. Studies in knockout mice indicated that the central effect of Ang II on alcohol consumption is mediated by the angiotensin receptor AT1 whereas the AT2 receptor and the bradykinin B2 receptor are not involved. Furthermore, the dopamine concentration in the ventral tegmental area (VTA) is markedly reduced in rats with low central Ang II, strengthening our hypothesis of a role of dopaminergic transmission in Ang II-controlled alcohol preference. Our results indicate that a distinct drug-mediated control of the central RAS could be a promising therapy for alcohol disease.

Role of angiotensin II and the subfornical organ in the pharmacological actions of ethanol

AIMS

The current study was designed to evaluate if angiotensin II mediates the hypothermic effects of ethanol, and to determine if the effects of angiotensin are mediated centrally. We also tested the hypothesis that the subfornical organ (SFO) is a site responsible for the alterations in body temperature and aerial righting reflex mediated by ethanol and for the modulation of ethanol consumption in rats.

METHODS

Male Sprague-Dawley rats were used in a series of experiments to evaluate the role of both peripheral and central administration of losartan, a selective angiotensin type 1 receptor antagonist on ethanol-induced hypothermia. Subsequent studies were undertaken in SFO-lesioned rats to evaluate the effects of SFO-lesion on alcohol intake, the thermal response to alcohol and angiotensin, and the aerial righting reflex.

RESULTS

Selective antagonism of the angiotensin II type 1 receptor, administered either peripherally or centrally, attenuated not only the fall in colonic temperature but also attenuated the transient rise in tail skin temperature that was associated with administration of ethanol. The thermal responses to both angiotensin and ethanol were similarly attenuated in SFO-lesioned rats. Likewise the aerial righting reflex, which has previously been shown to be impaired by losartan treatment, was also significantly attenuated in SFO-lesioned animals. Alcohol intake, as determined by a 48 h, two-bottle preference test also revealed that SFO-lesioned animals consumed significantly less alcohol (ethanolic beer) than did controls.

CONCLUSION

Collectively, the results demonstrate that ethanol-induced temperature responses are mediated by the renin-angiotensin system and that this interaction is mediated centrally. In addition, the results demonstrate that the SFO is a site that mediates several neurobiological effects of ethanol, possibly via the renin-angiotensin system.

Neutral endopeptidase and alcohol consumption, experiments in neutral endopeptidase-deficient mice

Alcohol consumption was investigated in mice which were rendered deficient in the peptide-degrading enzyme neutral endopeptidase (EC 3.4.24.11) (NEP-/-) by gene targeting and compared to alcohol consumption in corresponding wild type mice (NEP+/+). Mice were offered a free choice to drink tap water or 10% alcohol. The NEP-/- mice consumed significantly more alcohol ( approximately 42%) than the NEP+/+ mice, whereas no significant differences were observed in the total fluid consumption. The daily food consumption of alcohol naive NEP-/- animals was elevated ( approximately 29%). Furthermore, the activities of peptidases closely related to neutral endopeptidase were analysed ex vivo in several brain regions from NEP-/- and NEP+/+ mice not treated with alcohol. There was no obvious compensation for the total loss of neutral endopeptidase by the functionally related peptidases angiotensin-converting enzyme and aminopeptidase N. In vitro, the degradation of exogenously applied [Leu(5)]enkephalin was not reduced in membrane preparations of those brain regions assayed in NEP-/- mice. A small reduction in [Leu(5)]enkephalin degradation was detected in striatal membrane preparations of NEP-/- mice, if aminopeptidase N was additionally blocked by bestatin or amastatin.

Angiotensin II stimulates intake of ethanol in C57BL/6J mice

The influence of intracerebroventricular (i.c.v.) infusion of angiotensin II on intake of water and ethanol solutions was determined in C57BL/6J mice. Compared to other mice, C57 mice do not show an aversion to ethanol solutions. With both water and ethanol solutions available, the C57 mice consumed 40-60% of their total daily fluid intake as ethanol solution when the concentration of ethanol solution offered was 4-14%. When given a choice between 0.3 M KCl and either 4 or 10% ethanol solution, the mice clearly preferred the ethanol solution. With water only available, i.c.v. infusion of angiotensin II increased intake from 3-5 mL/day (baseline) to 11-12 mL/ day (Day 4 of infusion). A similar increase in intake occurred in mice with access to a nonpreferred solution of 0.3 M KCl. In comparison, when only 4% ethanol solution was available, angiotensin II increased intake to 7-8 mL/day, and when only 10% ethanol solution was available, intake was transiently increased. The results demonstrated that thirst for water caused by i.c.v. infusion of angiotensin II in C57 mice is similar to that observed in BALB/C mice. Unlike BALB/C mice, however, i.c.v. infusion of angiotensin II stimulated intake of ethanol solution. The failure of angiotensin II to cause a large increase in 4% ethanol solution or a sustained increase in 10% ethanol solution intake does not seem to be caused by an aversion to the taste of ethanol solution, but most likely due to postingestional factors.

Intracerebroventricular infusion of angiotensin II increases water and ethanol intake in rats

The influence of prolonged ingestion of ethanol on stimulation of water or ethanol intake by intracerebroventricular infusion of ANG II was evaluated in rats. Animals were maintained for 5-6 mo with either 10% ethanol solution or water as their only source of fluid. In both groups of rats, infusion of ANG II caused a large increase in water intake (7-fold) and a lesser increase in 10% ethanol intake (2-fold). The effect of ANG II on the volume of ethanol solution ingested, however, was inversely related to the concentration of the ethanol solution. As the concentration of ethanol solution was decreased, frequency and duration of drinking bouts increased. The intake of sweetened 10% ethanol solution or commercially produced wine during infusion of ANG II was similar to the intake of 10% ethanol and not related to taste preference. In conclusion, chronic consumption of ethanol solution did not appear to adversely effect ANG II stimulation of water intake. The intake of ethanol solution during infusion of ANG II was inhibited by a direct effect of ingested ethanol and/or by indirect effect from metabolized ethanol.

Changes in angiotensin II receptors in dopamine-rich regions of the mouse brain with age and ethanol consumption

The density of angiotensin II (Ang II) receptors was determined in three dopaminergic nerve terminal-rich brain regions (caudate putamen, nucleus accumbens, and ventral pallidum) of mice that were given either water (control) or 20% w/v ethanol (EtOH) to drink for either 2-8 weeks (young) or 46 weeks (old). The receptors were labeled with 125I-sarcosine1, isoleucine8 angiotensin II (125I-SI Ang II) and measured by quantitative densitometric image analysis (receptor autoradiography) or by saturation binding assays on homogenates of these brain regions. The selective AT2 receptor subtype antagonist PD 123319 (10 microM) was used to inhibit 125I-SI Ang II binding to AT2 receptors to determine AT1 receptor density in brain sections. In young control mice the density of Ang II receptor binding sites in the caudate putamen was 407+/-26 fmol/g, in the nucleus accumbens the density was 346+/-27 fmol/g, and in the ventral pallidum the density was 317+/-27 fmol/g. Less than 5% of specific 125I-SI Ang II binding was displaced by PD 123319, suggesting that nearly all of the Ang II receptors in these brain regions were the AT1 subtype. The Bmax in homogenates of these three regions in young control mice was 11.0+/-2.1 fmol/mg protein. The KD was 0.49+/-0.13. Ang II receptors in old mouse brains were decreased, respectively, by 32%, 35% and 30% in the caudate putamen, nucleus accumbens and ventral pallidum (p<0.001). Ang II receptors were slightly, but not significantly increased in both young and old EtOH-consuming mice.

Histaminergic activation of endogenous angiotensin II fails to inhibit alcohol intake in rats

Demonstrations that alcohol intake can be inhibited by pharmacological activation of the renal renin-angiotensin system (RRA) or injection of angiotensin II (ANG II) in rats led to this study of a role for endogenous ANG II in inhibition of alcohol intake in rats. Relatively small doses of histamine, above threshold for eliciting drinking of water and activation of the RRA, were injected SC in adult male Sprague-Dawley rats with access to 3.0% alcohol in 45-min one-bottle alcohol tests and in two-bottle tests in which alcohol and water were available at the midpoint of the 12-h dark phase. The 0.312 and 1.25 mg/kg doses of SC histamine elevated plasma renin activity to levels similar to those in rats that had just eaten food. Neither dose of histamine affected alcohol intake in one-bottle tests. A relatively large 10 mg/kg dose of histamine increased alcohol intake in a one-bottle test, but decreased alcohol intake and increased water intake in two-bottle tests. The inhibitory effect of the 10 mg/kg dose of histamine on alcohol intake was completely blocked by SC 10 mg/kg losartan, a selective AT1 angiotensin receptor antagonist. This 10 mg/kg dose of losartan given alone, however, failed to increase alcohol intake in one- or two-bottle tests. These results generally do not support a role for endogenous ANG II as an inhibitory physiological signal in the control of alcohol ingestion in rats, because histaminergic activation of RRA, using small but physiologically meaningful doses of histamine, failed to inhibit alcohol intake.

Effect of captopril on voluntary consumption of ethanol, water and solid food by UChA and UChB rats

Angiotensin converting enzyme inhibitors (ACEI) have been reported to reduce ethanol consumption in rats, but it is unclear whether this effect is specific for ethanol or secondary to effects on appetite or satiation for calories or water. In the present study we assessed the effect of captopril, an ACEI, on the voluntary consumption of 10% ethanol solution, water and solid food in our strain of rats genetically selected for their voluntary consumption of ethanol, namely UChA (low consumer) and UChB (high consumer). Captopril (30 mg/kg) was injected intraperitoneally for 3 consecutive days to UChA and UChB rats and ethanol, water and food intake were measured before, during and after captopril treatment; these results were compared with those produced by a control saline solution. Results showed that captopril produced a significant reduction of alcohol voluntary consumption in UChB but not in UChA rats. However, this effect was not specific for ethanol since captopril also induced a significant decrease in food intake leading to a loss of weight in both rat strains, suggesting that it seems to be secondary to changes in appetite for calories.

Glucose and the insulin-releasing drug tolbutamide attenuate the effects of morphine and angiotensin on alcohol consumption

Animals studies have shown that insulin injections reduce alcohol intake, implicating glucoregulatory processes in alcohol consumption. Angiotensin (ANG) II reduces alcohol intake and promotes glycogen breakdown in the liver but no studies have assessed the role of glucoregulatory processes in ANG II's effect. Similarly, glucose injections attenuate the analgesic and cognitive effects of opiates, yet no studies have assessed the effect of glucose on the well-documented ability of opiates to enhance alcohol consumption. The present experiments further examine the role of glucoregulatory processes in alcohol intake by assessing the effect of glucose injections on morphine-enhanced alcohol consumption and by evaluating the effect of the insulin-releasing drug, tolbutamide, on ANG II-reduced alcohol consumption. Adult male Wistar rats acquired alcohol drinking using the limited access procedure that offers daily 40-min access to both 6% w/v alcohol and water and ensures reliable alcohol drinking in bouts large enough to produce pharmacologically relevant intakes. Experiment 1: after intake stabilized, four groups of rats were first pretreated with vehicle injections and in the next phase, three of the four groups received either 50, 100, or 200 mg/kg glucose intraperitoneally (i.p.) prior to access to alcohol. Neither the vehicle injections nor any of the glucose doses had an effect on alcohol intake. In the final phase all groups continued to receive their respective glucose doses or vehicle but were now also treated with 5 mg/kg morphine sulphate i.p. prior to alcohol access. Morphine stimulated alcohol intake to a similar degree in all groups except the 200 mg/kg group, which showed a significant attenuation in morphine-enhanced alcohol intake. Experiment 2: after intake stabilized, different groups of rats were pretreated with vehicle injections and in the next phase received either 5, 25, 50, or 100 mg/kg tolbutamide or vehicle subcutaneously (s.c.) prior to alcohol access. The vehicle injections did not alter alcohol intake, and only the 100 mg/kg dose of tolbutamide produced a reduction in alcohol intake. In the final phase the groups continued to receive their respective doses of tolbutamide or vehicle but were also treated with 400 micrograms/kg ANG II s.c. immediately prior to alcohol access. ANG II reduced alcohol intake a similar extent in the groups pretreated with 5-50 mg/kg tolbutamide. However, the 100 mg/kg dose of tolbutamide significantly attenuated ANG II's ability to reduce alcohol intake. These results demonstrate that manipulations that engage glucoregulatory processes can influence the mechanism(s) by which morphine and angiotensin respectively increase and decrease alcohol drinking.

The dipsogen angiotensin II does not stimulate ethanol intake in mice

Mice that were habituated to drinking ethanol solution and mice that had drunk water only (naive mice) were given an ICV infusion of angiotensin II (Ang II) at 2.9 ng/h for 8 days to determine the effect of chronic ethanol intake on the ingestive response to this potent dipsogen. Ang II infusion in alcohol-naive mice increased daily water intake from 3.7 +/- 0.2 ml (mean +/- SE, n = 6) to 11.0 +/- 1.5 ml on day 4 (p < 0.001) and to 18.3 +/- 2.6 ml on day 8 (p < 0.001). In subsequent experiments, mice had access to 4% ethanol solution up to day 4 and then to water for 4 days during the Ang II infusion. Alcohol-naive mice did not increase daily fluid intake until the water was provided on day 5; intake increased to 17.5 +/- 2.3 ml on day 8 (p < 0.001, n = 7). Mice accustomed to drinking 4% ethanol (4.3 +/- 0.3 ml/day) also did not increase intake until the water was provided; intake reached 22.9 +/- 3.0 ml of water on day 8 (p < 0.001, n = 7). Mice accustomed to drinking 10% ethanol behaved similarly (n = 4). Thus, alcohol-naive or -habituated mice did not respond to this dipsogenic stimulus until water was available; the thirst for water was unimpaired. Preference-aversion tests showed that mice drank little or no 4% ethanol (or even 2% ethanol) when water was also available. Taste aversion, plus previous experience from ingestion of ethanol in habituated mice, may explain the rejection of ethanol to quench Ang II-induced thirst. Experimental results obtained using other aversive solutions, 3 mM quinine and 300 mM KCl, suggest that postingestional, metabolic effects of solutes may also contribute to such rejection.

Angiotensin II reduces alcohol intake and choice in water- or food-restricted rats

Two experiments were conducted to assess the effects of administration of the neuropeptide and hormone angiotensin II (AII) on ethanol intake and choice. First, 18 male Wistar rats were water deprived for 23 h and given access to 5% w/v ethanol for 30 min, followed by 30 min of access to water; food was ad lib. Following adaptation to this schedule, rats were randomly assigned to receive an IP injection of 0, 100, or 200 micrograms/kg of AII at either -30 or 0 min prior to ethanol access. Each AII injection decreased ethanol intake only if injected immediately before access; water and food intake were unaffected. Secondly, rats were given food daily at 2% of body weight with ad lib water and randomly assigned to receive either only water or 4% w/v ethanol ad lib on alternate days. Following adaptation, rats were randomly assigned to receive IP saline or 200 micrograms/kg of AII prior to presentation of a choice of ethanol or water for 1 h. AII reduced ethanol intake and increased water intake at 0-30 min after injection. Results confirm previous reports of inhibition of alcohol consumption by peripheral AII, and indicate a temporal constraint on AII's effect, which is consistent with a role as a short-term satiety factor.

Acetaldehyde inhibits serum aminopeptidases

Aminopeptidase A (APA)- and aminopeptidase M (APM)-like activity were assayed in Moni-Trol ES with L-alpha-aspartyl-beta-naphthylamide and L-alanyl-beta-naphthylamide, respectively. Upon preincubation of the serum with 89.4, 223.5, and 447 mM acetaldehyde at room temperature for 30 min, a reduction in 26.8%, 55.3%, and 75.8% aminopeptidase A activity was observed. Similarly, aminopeptidase M activity was reduced by 26.5% and 53.1% upon preincubation with 223.5 and 447 mM acetaldehyde. Ethanol at 84.9, 212.3, and 427.9 mM did not significantly affect the enzymic activity. Because aminopeptidase A and aminopeptidase M also degrade the pressor substance, angiotensin II, it is suggested that inhibition of aminopeptidase A- and aminopeptidase M-like activity by acetaldehyde, the product of ethanol metabolism, may lead to higher levels of circulating angiotensin II and, consequently, hypertension, in alcoholics. The hydrolysis of lysine-p-nitroanilide, an aminopeptidase B substrate, was also inhibited upon addition of acetaldehyde to Moni-Trol ES serum.

Intracerebroventricularly infused angiotensin II or III do not alter voluntary alcohol intake in rats

Subcutaneous injections of angiotensin (ANG) II or III in the periphery reduce alcohol intake and raise water intake. These peptides do not cross the blood-brain barrier and cannot reach the angiotensin receptor-rich sites surrounding the lateral and third ventricles. To examine the effect on alcohol intake of ANG II and III at these ventricular sites, groups of rats were first trained to drink alcohol using a limited access procedure, then surgically prepared with chronic indwelling lateral or third ventricular cannulae, and then reoffered daily 40-min access to alcohol. Neither ANG II (25-200 ng) nor ANG III (25-100 ng) had any effect on alcohol consumption at either of the two ventricular sites. Water consumption was significantly enhanced by both peptides at both sites and could be attenuated by prior treatment with the ANG II antagonist Sar1Thr8-ANG II. The SC administration of ANG II was able to produce a significant reduction in alcohol drinking. These findings demonstrate that ICV administered ANG II or ANG III do not modulate alcohol drinking and that changes in alcohol intake do not result from the thirst promoted by ANG II. Sites in the periphery may be more involved in the interaction between angiotensin and alcohol consumption.

Increased alcohol consumption in weight-reduced rats is modulated by the renin-angiotensin system

Weight reduction and food restriction increase the self-administration of alcohol and other drugs of abuse, but the underlying physiological mechanisms have not been identified. Because weight reduction alters angiotensin (ANG) II activity, and ANG II is known to modulate alcohol intake, ANG II may play a role in the enhanced alcohol consumption of food-deprived weight-reduced rats and in the drop in alcohol intake when these rats are refed. Two groups of rats were reduced to and maintained at 80% of their free feeding weights and offered daily 40 min access to a 6% (w/v) alcohol solution and water. Water was available ad lib. After alcohol intake stabilized, one group was given daily injections of the angiotensin converting enzyme inhibitor captopril (5.0 mg/kg) for 6 days while the other group received the saline vehicle. Following this, each group continued to receive either captopril or vehicle injections but was returned to ad lib feeding. Captopril did not alter alcohol intake when the rats were food-deprived and weight-reduced, but did significantly attenuate the decline in alcohol consumption compared to the vehicle group when both groups were refed and regaining weight. These findings suggest that the increase in alcohol intake with food restriction and its decline following refeeding are, in part, related to changes in ANG II activity.

A relationship between increased voluntary alcohol preference and basal hypercorticosteronemia associated with an attenuated rise in corticosterone output during stress

Some of the multiple biological effects of stress include activation of a variety of neuroendocrine systems, resulting in enhanced secretion of many hormones, including corticosterone, as well as facilitation of drug-seeking behavior. Therefore, we have examined the potential relationship between voluntary alcohol consumption (VAC) and corticosterone output profile using: (1) selectively bred alcohol-preferring (P) and nonpreferring (NP) rats; and (2) outbred male Holtzman Sprague-Dawley rats selected for (a) low basal corticosterone (< 2 micrograms/mg Cr) and high stimulation (> 250%) (L-H rats), and (b) high basal corticosterone (> 4 micrograms/mg Cr) and low stimulation of corticosterone output on 24-hour fasting stress (< 125%) (H-L rats). The results of this study show: (a) the corticosterone output profiles of P and NP rats were similar to those of H-L and L-H rats, respectively; and (b) the H-L rats exhibited significantly higher VAC than the L-H rats. In conclusion, these data suggest that basal hypercorticosteronemia associated with attenuated rise in corticosterone output during stress may be associated with increased VAC.

Dietary salt and voluntary ethanol consumption in golden hamsters

Adult male golden hamsters were maintained on powdered Purina chow and tap water, and were permitted continuous access to either a 15% or a 30% ethanol solution (v/v); after an initial 4-5 weeks of ethanol availability, hamsters had stabilized their intakes and were deriving an average of 1.25 and 1.96 g/day of absolute ethanol from the 15% and 30% solutions, respectively. When salt was added to the diet in increasing concentrations ranging from 4% to 10% over a period of 40 days, hamsters reduced chow-derived calories by up to 35%, increased tap water consumption by up to 50%, and increased consumption of ethanol solutions by up to 100%; when unadulterated Purina chow was reinstated, intakes of chow-derived calories, tap water, and ethanol solutions returned to baseline levels. Hamsters that were continuously maintained on unadulterated Purina chow, but with chow-derived calories matched to that of animals on the salt-adulterated diet, significantly increased their ethanol intake, but not their tap water intake; the increase in their ethanol intake was only about half as large as that of hamsters that had salt added to the diet, but the increase persisted even after ad lib feeding was reinstated. The results indicate that the addition of salt to the diet of hamsters produces large increases in ethanol consumption; furthermore, the increased ethanol intake is not simply the result either of a nonselective increase in fluid consumption or of the reduction in food intake that accompanies the addition of salt to the diet. Results are related to the possible role of the renin-angiotensin system in the control of ethanol consumption in the golden hamster.

The reduction in alcohol intake produced by enalapril is not attenuated by centrally administered angiotensin inhibitors

Angiotensin-converting enzyme (ACE) inhibitors, which prevent the conversion of angiotensin I to angiotensin II, reduce alcohol intake when injected peripherally. The mechanism by which ACE inhibitors produce this effect on alcohol intake is unknown. A rise in the biosynthesis of angiotensin II in the periphery is known to reduce alcohol intake. In this experiment, we examine the possibility that the reduction in alcohol intake produced by an ACE inhibitor, enalapril, is mediated by a rise in angiotensin II in the brain. Enalapril, 20 mg/kg, injected intraperitoneally, produced a 40% reduction in alcohol intake. This reduction was not attenuated by the concurrent administration into the lateral ventricle of either the ACE inhibitors captopril or ceranapril (1, 10, or 25 micrograms), or the angiotensin II receptor antagonist Sar1-Thr8-Angiotensin II (5 micrograms). These findings suggest that the ACE inhibitors do not reduce alcohol intake by raising angiotensin II in the brain.

Brain angiotensin receptor subtypes in the control of physiological and behavioral responses

This review summarizes emerging evidence that supports the notion of a separate brain renin-angiotensin system (RAS) complete with the necessary precursors and enzymes for the formation and degradation of biologically active forms of angiotensins, and several binding subtypes that may mediate their diverse functions. Of these subtypes the most is known about the AT1 site which preferentially binds angiotensin II (AII) and angiotensin III (AIII). The AT1 site appears to mediate the classic angiotensin responses concerned with body water balance and the maintenance of blood pressure. Less is known about the AT2 site which also binds AII and AIII and may play a role in vascular growth. Recently, an AT3 site was discovered in cultured neoblastoma cells, and an AT4 site which preferentially binds AII(3-8), a fragment of AII now referred to as angiotensin IV (AIV). The AT4 site has been implicated in memory acquisition and retrieval, and the regulation of blood flow. In addition to the more well-studied functions of the brain RAS, we review additional less well investigated responses including regulation of cellular function, the modulation of sensory and motor systems, long term potentiation, and stress related mechanisms. Although the receptor subtypes responsible for mediating these physiologies and behaviors have not been definitively identified research efforts are ongoing. We also suggest potential contributions by the RAS to clinically relevant syndromes such as dysfunctions in the regulation of blood flow and ischemia, changes in cognitive affect and memory in clinical depressed and Alzheimer's patients, and angiotensin's contribution to alcohol consumption.

Forebrain circumventricular organs mediate captopril-enhanced ethanol intake in rats

Chronic peripheral treatments with low doses of the angiotensin-converting enzyme inhibitor, captopril, enhance daily intakes of dilute ethanol solutions in rats as they do the intakes of water and saline solutions. Placing captopril into the drinking water or infusing it SC increases daily intake of 6% (v/v) ethanol from 30-100% over 4-12 days of treatment. The present study examined the effects of electrolytic lesions either of the subfornical organ (SFO) or of the organum vasculosum laminae terminalis (OVLT), on captopril-enhanced ethanol intake. Captopril was infused in minipumps at 5 mg/day for 14 days. The intake of 6% (v/v) ethanol was abolished by SFO lesions and was temporarily reduced by OVLT lesions. The SFO, in particular, is essential for the expression of enhanced ethanol intake during low-dose peripheral captopril administration. Local angiotensin II synthesis and receptor activation at the SFO appear to be the mechanism of the enhanced ethanol drinking during captopril.